Nabriva Therapeutics, a biopharma focused on treating bacterial infections, has appointed a new chief medical officer in the form of Jennifer Schranz.
Dr Schranz joins Nabriva from Irish biopharma Shire, with nearly two decades of experience in clinical development and medical affairs.
Commenting on the appointment, Dr Colin Broom, chief executive officer of Nabriva, said: “Jennifer has broad expertise in infectious diseases and internal medicine with extensive experience in both clinical development and medical affairs for small molecules and biologics.
“She brings a track record of successful navigating the regulatory submission and approval process, as well as leading medical affairs activities and will be an invaluable member of our team as we continue to advance the legamulin programme toward a potential approval for the treatment of community-acquired bacterial pneumonia.”
Dr Schran’z new role will see her lead clinical development and medical affairs, contributing to the company’s business development strategy.
Her career has seen her hold positions at Shire, ViroPharma, Pfizer, GlaxoSmithKline and Merck & Co.